WO1996032118A1 - Use of nitric oxide-releasing agents to treat impotency - Google Patents
Use of nitric oxide-releasing agents to treat impotency Download PDFInfo
- Publication number
- WO1996032118A1 WO1996032118A1 PCT/US1996/004889 US9604889W WO9632118A1 WO 1996032118 A1 WO1996032118 A1 WO 1996032118A1 US 9604889 W US9604889 W US 9604889W WO 9632118 A1 WO9632118 A1 WO 9632118A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- nitric oxide
- chain alkyl
- branched chain
- compound
- Prior art date
Links
- 0 C*(C)C(CC1)NCCC1(*)C1CCCCC1 Chemical compound C*(C)C(CC1)NCCC1(*)C1CCCCC1 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
- C08F8/32—Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
Definitions
- the present invention relates to a method of treating impotency in a male, and more particularly, to the use of certain nitric oxide-releasing agents to treat impotency.
- the present invention also relates to nitric oxide delivery means comprising nitric oxide- releasing agents for use in the method.
- Penile erection and detumescence involve a complex interaction of direct neuronal activation combined with the release of endothelial derived contractile and relaxant factors.
- a variety of neurotransmitter substances and vasoactive modulators have been described. Of these, nitric oxide appears to play a primary role in the development of an erection.
- Cavernosal smooth muscle relaxation is one of the primary events in penile erection. Although it is believed to be initiated by the synthesis and release of NO from nonadrenergic-noncholinergic neurons of the corpus cavemosum (Kimura et al., Nippon Hinyokika Gakkai Zasshi 84(9): 1660-1664 (1993); Rajfer et al. , N. Engl. J. Med. 326(2): 90-94 (1992); Knispel et al., Urol. Res. 20(4): 253-257 (1992); Burnett et al., Science 257(5068): 401-403 (1992); and Mills et al. , Biol. Reprod.
- therapies for erectile dysfunction include needle injection of a vasodilator drugs directly into the penis; a vacuum constriction device (VCD) , which pulls blood into the penis and holds it there with a constriction ring; a surgical implant, which provides rigidity; oral medication, such as yohimbine, which appears to have beneficial effects in only a small proportion of patients; psychological therapy, for which few data exist on long term benefit; and vascular surgery, which is appropriate in only a very small number of patients. All six therapies have significant drawbacks. In fact, they are so limited in appeal that fewer than ten percent of men with erectile dysfunction have adopted any one of the therapies at all. In addition, each of these therapies suffers from exceedingly high rates of discontinuance for reasons that are not entirely related to the therapy, itself. There remains a need, therefore, for an effective method of treating impotency.
- Nitric oxide has been utilized as a means of studying penile erection and penile dysfunction due to diabetes and venous leakage, for example.
- the potential usefulness of nitric oxide to treat impotence has been discussed by McGuffey (Am. Pharm. NS33(7): 20 (1993)).
- Nitric oxide in its pure form is a highly reactive gas having limited solubility in aqueous media (WHO Task Group on Environmental Health Criteria for Oxides of Nitrogen, Oxides of Nitrogen. Environmental Health Criteria 4 (World Health Organization: Geneva, 1977)). Nitric oxide, therefore, is difficult to introduce reliably into most biological systems without premature decomposition.
- a number of compounds have been developed that are capable of delivering nitric oxide in a pharmacologically useful way. Such compounds include compounds that release nitric oxide upon being metabolized and compounds that release nitric oxide spontaneously in aqueous solution.
- S-Nitroso-N- acetylpenicillamine has been reported to release nitric oxide in solution and to be effective at inhibiting DNA synthesis (Garg et al., Biochem. and BioPhvs. Res. Co m.. HI, 474-479 (1990)).
- SNP has been administered to primates for purposes of studying the physiology and pharmacology of erection (Hellstro et al., J. Urol. 151(60: 1723-1727 (1994)). Intracavernosal injection of SNP induced erections with dose-dependent increases in cavernosal pressure and penile length.
- the NO donor linsidomine chlorohydrate, otherwise known as 3-morpholinosydnonimine or SIN-1 was administered to 30 human patients with erectile dysfunction caused by venous leakage (Wegner et al. , Urology 42(4): 409-411 (1993)) and was less effective than prostaglandin El (PGEl) in treating the dysfunction in over two-thirds of the patients treated.
- PEP prostaglandin El
- SIN-1 was also found to be less effective than SNP in relaxing isolated rabbit corpus cavemosum (Holmquist et al., J. Urol. 150(4): 1310-1315 (1993)). More promising results with SIN-1 were obtained in a 63-patient study carried out by Stief et al. (J. Urol. 148(5): 1437-1440 (1992)).
- activation of SIN-l by oxygen produces both NO and superoxide ion, two species that can combine with one another to produce the potent oxidant, ONOO " .
- the potential to produce this toxic by-product is believed to limit the utility of such sydnonimine drugs.
- nitric oxide-nucleophile complexes Numerous nitric oxide-nucleophile complexes also have been described, e.g., by Drago, ACS Adv. Chem. Ser.. 3_6_, 143-149 (1962). See also Longhi and Drago, Inor . Chem.. Z, 85 (1963). Some of these complexes, known as NONOates, evolve nitric oxide on heating or hydrolysis (Maragos et al., J. Med. Chem.. 34. 3242-3247 (1991)) .
- NONOates having reproducible half- lives ranging from 2 seconds to 20 hours have been prepared. They can be O-alkylated to provide either spontaneous NO-generators with half-lives of up to a week or more or prodrugs that cannot release NO at all until the oxygen substituent is removed etabolically.
- the NONOate function can be coordinated via the two oxygen atoms to metal centers; it can be attached to natural products, such as sper ine (a constituent of human semen) and peptides; and it can be bound in solid polymeric matrices to provide a point source of NO.
- a compound containing more than one nucleophile residue (such as, for example, the polya ine, sper ine) can be bound to more than one NONOate group, to thereby provide a single NONOate molecule with bi-or polyphasic NO release rates.
- the NONOates constitute a most advantageous series of compounds on which to base NO donor drug development efforts.
- Nitric oxide/nucleophile complexes that release nitric oxide in aqueous solution are disclosed in U.S. Patent Nos. 4,954,526, 5,039,705, 5,155,137,
- nitric oxide/nucleophile complexes can be incorporated into polymers in order to overcome this limitation by enabling concentrated and localized release of NO at a given site in a controllable and predictable manner such that effective dosing can be realized. This imparts a tremendous advantage to the technology for the treatment of erectile dysfunction.
- the present invention provides a method of treatment for impotency in a male animal that overcomes the above-described disadvantages of currently available treatment methods by employing NONOates as nitric oxide- releasing agents in the form of polymers, pharmaceutical compositions, and various delivery means comprising such compositions and polymers. Accordingly, the present invention also seeks to provide delivery means for use in the present inventive method.
- the present invention provides a method of treatment for impotency in a male animal, including a human.
- the method comprises the administration of a nitric oxide-releasing agent, which is capable of providing a penile erection-inducing amount of nitric oxide to the male animal and which includes a nitric oxide-releasing [N 2 0 2 ] functional group.
- the nitric oxide-releasing agent can be a compound comprising a nitric oxide-releasing [N 2 0 2 ] functional group, it can be a polymer to which is bound a nitric oxide-releasing
- the nitric oxide-releasing agent provides NO to the penis of an impotent male animal in an amount sufficient to cause a penile erection.
- the delivery means can be coated with or made of a nitric oxide-releasing agent in the form of a polymer and enables the controllable and predictable release of NO to the penis in such a manner that effective therapeutic dosing of impotency is realized.
- the delivery means can be biodegradable. Delivery means comprising the nitric oxide-releasing agent are also provided. Brief Description of the Drawings Figure 1 illustrates an exploded view of one embodiment of a transurethral therapeutic device for delivery of the nitric oxide-releasing agent to the urethra.
- Figure 2 is a graph of corporal pressure (mm Hg) versus dose ( ⁇ g/200 ⁇ l) .
- Figure 3 is a graph of penile length change versus dose ( ⁇ g/200 ⁇ l) .
- the present invention provides a method for the treatment of impotency in a male animal, including a human.
- the method involves the administration to a male animal, in particular a human, of a nitric oxide- releasing agent.
- the nitric oxide-releasing agent can be a compound comprising a nitric oxide-releasing [N 2 0 2 ] functional group or a polymer to which is bound a nitric oxide-releasing [N 2 0 2 ] functional group or a delivery means, such as a transurethral applicator, a penile implant, a dermal patch or a condom, comprising such a compound or polymer.
- “Bound to a polymer” means that the [N 2 0 2 ] functional group is associated with, part of, incorporated with or contained within the polymeric matrix either physically or chemically. Physical association or bonding of the N 2 0 2 " functional group to the polymer may be achieved by coprecipitation of the polymer with a nitric oxide/nucleophile complex as well as by covalent bonding of the N 2 0 2 " group to the polymer.
- Chemical bonding of the N 2 0 2 " functional group to the polymer may be by, for example, covalent bonding of the nucleophile moiety of the nitric oxide/nucleophile adduct to the polymer such that the nucleophile residue to which the N 2 0 2 " group is attached forms part of the polymer itself, i.e., is in the polymer backbone or is attached to pendant groups on the polymer backbone.
- the manner in which the nitric oxide-releasing N 2 0 2 " functional group is associated, part of, or incorporated with or contained within, i.e., "bound,” to the polymer is inconsequential to the present invention and all means of association, incorporation and bonding are contemplated herein.
- the delivery means can be coated with or made of a nitric oxide-releasing agent in the form of a polymer and enables the controllable and predictable release of NO to the penis in such a manner that effective therapeutic dosing of impotency is realized.
- a nitric oxide-releasing agent in the form of a polymer and enables the controllable and predictable release of NO to the penis in such a manner that effective therapeutic dosing of impotency is realized.
- “Nitric oxide delivery means” is meant to include the many forms in which the nitric oxide-releasing agent can be configured, such as a transurethral applicator, an implant, drug pump, catheter, self-adhering means, liposome, microparticle, solution, microsphere, bead, disk or other pharmaceutical composition as described more fully below.
- the delivery means can be biodegradable.
- the nitric oxide-releasing agent provides NO to the penis of an impotent male animal in an amount sufficient to cause a penile erection. Determination of what amount is sufficient to induce a penile erection is as described below with respect to dosages. Whether or not a particular animal suffers from impotency is readily determined. Whether or not a particular animal is at risk for impotency can be assessed by those of skill in the art by taking into account known risk factors. Factors such as diabetes mellitus or venous leakage are likely to place a man at risk for impotency.
- the present invention also provides various nitric oxide delivery means for use in the present inventive method as described more fully below.
- the nitric oxide-releasing [N 2 0 2 ] functional group is X N(0)N0] or [N(0)NO- ⁇ -X, wherein X is an organic or inorganic moiety bonded to the - N(0)NO] or [N(O) on ⁇ functional group.
- the compound containing the [N 2 0 2 ] functional group can be incorporated into or be part of a polymer.
- the [N 2 0 2 ] group can be covalentiy bonded in the polymer by way of the moiety X. Incorporation of the N 0 2 " functional group into a polymer enables localized release of NO to the penis. "Localized release" means into or adjacent to the corpus cavemosum.
- Localized release enhances the selectivity of action of the nitric oxide-releasing [N 2 0 2 ] functional group. If [N 2 0 2 ] functional groups attached to the polymer are localized, then the effect of their NO release will be concentrated in the tissues with which they are in contact. If the polymer is soluble, selectivity of action can still be arranged, for example, by attachment to or derivatization of an antibody specific to the target tissue. Similarly, attachment of [N 2 0 ] functional groups to small peptides that mimic the recognition sequences of ligands for important receptors provides localized, concentrated NO release, as would attachment to oligonucleotides capable of site-specific interactions with target sequences in a nucleic acid.
- incorporation of the [N 2 0 2 ] functional group into a polymer can reduce the propensity of the nitric oxide/nucleophile adduct for the relatively rapid release of NO. This prolongs the release of NO by the [N 2 0 2J functional group, and allows for efficient dosing to achieve a penile erection and, possibly, concomitant reduction in the frequency of dosing.
- N 2 0 2 groups near the surface of the particle should be available for rapid release while those that are more deeply imbedded are sterically shielded, requiring more time and/or energy for the nitric oxide to work its way into the medium.
- increasing positive charge in the vicinity of an N 2 0 2 ⁇ functional group also tends to increase the halflife of nitric oxide generation.
- the mechanism of this rate retardation may be attributable simply to repulsive electrostatic interactions, i.e., increasing the number of H + -repelling positive charges in the vicinity of the N 2 0 2 " groups inhibits attack of positively charged H + ions on the N 2 0 2 " functional group and slows the rate of its H + - catalyzed decomposition.
- partially converted structures can be produced on less- than-exhaustive treatment with nitric oxide that after exposure to water contain a large number of positively charged ammonium centers surrounding the N 2 0 2 ⁇ group that electrostatically inhibit the approach of H + ions capable of initiating nitric oxide loss from the nitric oxide releasing N 2 0 2 " functional group.
- nitric oxide-releasing [N 0 2 ] functional groups that are bound to the polymer generally are capable of releasing NO in an aqueous environment spontaneously upon contacting an aqueous environment, i.e., they do not require activation through a redox reaction or electron transfer, such as is required for glyceryl trinitrate and SNP.
- Some of the nitric oxide/nucleophile complexes useful in the context of the present invention do require activation by particular means, but only as necessary to free the nitric oxide- releasing X-£-N(0)NO] ⁇ group in the vicinity of the penis or corpus cavemosum.
- covalent attachment of a protecting group to the anionic [N(0)N0] ⁇ function provides a means of postponing NO release until the molecule reaches the penis, where cells/tissues are capable of metabolically removing the protecting group.
- the polymer-bound, nitric oxide-releasing compositions of the present invention are capable of releasing NO in an aqueous solution, such a polymer preferably releases NO under physiological conditions.
- the nitric oxide-releasing [N 2 0 2 ] functional group is preferably a nitric oxide/nucleophile adduct, i.e., a complex of NO and a nucleophile, most preferably a nitric oxide/nucleophile complex which contains the anionic moiety X N(0)N0] " , wherein X is any suitable nucleophile residue.
- nitric oxide/nucleophile complexes are stable solids and are capable of delivering NO in a biologically usable form at a predictable rate.
- nitric oxide/nucleophile complexes include those having the following formulas:
- J is an organic or inorganic moiety, including, for example, a moiety which is not linked to the nitrogen of the [N 2 0 2 ] group through a carbon atom
- M* x is a pharmaceutically acceptable cation, where x is the valence of the cation, a is 1 or 2, and b and c are the smallest integers that result in a neutral compound, preferably such that the compound is not a salt of alanosine or dopastin, as described in U.S. Patent No. 5,212,204, incorporated herein by reference;
- R 1; R 2 , R 3 , R 4 , and R 5 are the same or different and may be hydrogen, C 3 _ 8 cycloalkyl, C 1-12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2,2-trichloro-t-butoxycarbonyl, and x, y, and z are the same or different and are integers from 2 to 12, as described in U.S. Patent No. 5,155,137, incorporated herein by reference;
- B is or —N N— 2 0 2 ⁇ ,
- R 6 and R 7 are the same or different and may be hydrogen, 3 - 8 cycloalkyl, C 1 _ 12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2,2-trichloro- t-butoxycarbonyl, f is an integer from 0 to 12, with the proviso that when B is the substituted piperazine moiety — N N-N 2 0 2 "
- f is an integer from 2 to 12, as described in U.S, Patent 5,250,550 incorporated herein by reference;
- R 8 is hydrogen, C 3 _ 8 cycloalkyl, C 1-12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-toluyl, t-butoxycarbonyl, or 2,2,2-tri-chloro-t-butoxycarbonyl
- R 9 is hydrogen or a C 1 -C 12 straight or branched chain alkyl, and g is 2 to 6, as described in U.S. Patent No. 5,250,550, incorporated herein by reference;
- R-* ⁇ and R 2 are independently selected from the group consisting of a straight chain or branched chain l ⁇ C 12 a ⁇ k yl group and a benzyl group, preferably such that no branch occurs on the alpha carbon atom, or else R ⁇ and R 2 , together with the nitrogen atom to which they are bonded, form a heterocyclic group, preferably a pyrrolidino, piperidino, piperazino or morpholino group, M +x is a pharmaceutically acceptable cation, and x is the valence of the cation, as described in U.S. Patent Nos. 5,039,705 and 5,208,233 and U.S. patent application Serial No. 08/017,270, filed February 12, 1993, and incorporated herein by reference; K [ (M) x ⁇ ' ( L) y (R 1 R 2 N-N 2 0 2 ) z ] (VI )
- M is a pharmaceutically acceptable metal, or, where x is at least two, a mixture of two different pharmaceutically acceptable metals, L is a ligand different from (R 1 R 2 N-N 2 0 2 ) and is bound to at least one metal, R 1 and R 2 are each organic moieties and may be the same or different (preferably where M is copper, x is one, L is methanol, and y is one, that at least one of R 1 or R 2 is not ethyl) , x is an integer of from 1 to 10, x' is the formal oxidation state of the metal M, and is an integer of from 1 to 6, y is an integer of from 1 to 18, and where y is at least 2, the ligands L may be the same or different, z is an integer of from 1 to 20, and K is a pharmaceutically acceptable counterion to render the compound neutral to the extent necessary, as described in U.S. Patent 5,389,675 and incorporated herein by reference; [R-N(H)N(NO)
- R is C _ 8 lower alkyl, phenyl, benzyl, or C 3 _ 8 cycoloalkyl, any of which R groups may be substituted by one to three substituents, which are the same or different, selected from the group consisting of halo, hydroxy, C ⁇ g alkoxy, -NH 2 , -C(0)NH 2 , -CH(O) , -C(0)OH, and -N0 2
- X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group selected from the group consisting of C 1 _ 8 lower alkyl, -C(0)CH 3 , and -C(0)NH 2
- y is one to three, consistent with the valence of X, as described in U.S. Patent No. 4,954,526 and incorporated herein by reference; and
- R ⁇ and R 2 are independently chosen from C j ., straight chain alkyl, C 1 _ 12 alkoxy or acyloxy substituted straight chain alkyl, C 2 _ 12 hydroxy or halo substituted straight chain alkyl, C 3 _ 12 branched chain alkyl, C 3 _ 12 hydroxy, halo, alkoxy, or acyloxy substituted branched chain alkyl, C 3 _ 12 straight chain olefinic and C 3 _ 12 branched chain olefinic which are unsubstituted or substituted with hydroxy, alkoxy, acyloxy, halo or benzyl, or ⁇ 1 and R 2 , together with the nitrogen atom to which they are bonded, form a heterocyclic group, preferably a pyrrolidino, piperidino, piperazino or morpholino group, and R 3 is a group selected from C 1-1 straight chain and C 3 _ 12 branched chain alkyl which are un
- polymers suitable for use in the present invention are polyolefins, such as polystyrene, polypropylene, polyethylene, polytetrafluorethylene, polyvinylidene difluoride, polyvinylchloride, polyethyleneimine, and derivatives thereof; polyethers, such as polyethyleneglycol; polyesters, such as poly(lactide/glycolide) ; polyamides, such as nylon; polyurethanes; starburst dendimers biopolymers, such as peptides or proteins (e.g., antibodies), nucleic acids (e.g., oligonucleotides), and the like.
- the physical and structural characteristics of the polymers suitable for use in the present invention are not narrowly critical, but rather will depend on the route and frequency of administration.
- the polymer can be biodegradable.
- nitric oxide-releasing agents can be administered in a wide variety of forms of delivery means. Any delivery means should adequately protect the integrity of the NO prior to its release and should control the release of the NO at such a rate, in such an amount, and in such a location as to serve as an effective means of treating the impotency.
- delivery means for local administration or administration for localized release include, but are not limited to, a penile implant, a drug pump, a drug- delivery catheter (pressure-driven, iontophoretic or transurethral) , a self-adhering means, a liposoroe, a microparticle, a microsphere, a bead, a condom, a dermal patch, a disk or other device.
- the advantages of local administration or localized release include the ability to attain effective concentrations of NO at the target site more quickly, the use of a smaller dose, and the realization of fewer toxic side effects than could occur on systemic administration and release.
- Delivery means for systemic administration for localized release include, but are not limited to, solutions, suspensions, emulsions, capsules, sachets, tablets, dermal (topical) patches, lozenges, aerosols, liposomes, microparticles, microspheres, beads, prodrugs, tissue-specific antibodies, small peptides that mimic ligand recognition sequences, and sequence-specific oligonucleotides as described above.
- the polymer, itself, may be structurally sufficient to serve as a form of delivery means.
- the polymer can be incorporated into or coated onto other matrices, substrates or the like, or can be microencapsulated or the like.
- the nitric oxide-releasing [N 2 0 2 ] functional groups can be bound to a polymeric support in a number of different ways.
- the compounds described above can be bound to the polymer by coprecipitation of such compounds with the polymer. Coprecipitation can involve, for example, solubilizing both the polymer and the nitric oxide/nucleophile compound and evaporating the solvent.
- Monomers containing the [N 0 2 ] group also can be dissolved in molten polymer, which, upon solidification when the temperature is lowered, contains a rather uniform distribution of [N 2 0 2 ] groups within the matrix.
- the [N 0 ] functional group can be attached to an atom in the backbone of the polymer, or it can be attached to a group pendant to the polymer backbone, or it can simply be entrapped in the polymeric matrix.
- the polymer includes, in its backbone, sites that are capable of reacting with NO to bind the NO for future release.
- the polymer is polyethyleneimine
- the polymer includes nucleophilic nitrogen atoms, which react with NO to form the [N 2 0 2 ] functional group at the nitrogen in the backbone.
- the polymer can contain, or be derivatized with, a suitable nucleophilic residue capable of reacting with NO to form the [N 2 0 2 ] functionality. Reaction of the polymer that contains a suitable nucleophilic residue, or of the suitably derivatized polymer, with NO thus provides a polymer- bound nitric oxide-releasing [N 2 0 2 ] functional group.
- nitric oxide- releasing agents of the present invention suitable methods of administering the nitric oxide- releasing agents of the present invention to a male animal, including a human male, are available, and, although more than one route can be used to administer a particular compound or polymer, a particular route can provide a more immediate and more effective result than another route.
- Pharmaceutically acceptable carriers are also well-known to those who are skilled in the art. The choice of carrier for a pharmaceutical composition will be determined in part by the particular composition, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions for use in the present invention.
- Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the polymer-bound composition dissolved in diluents, such as water or saline, (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as solids or granules, (c) suspensions in an appropriate liquid, and (d) suitable emulsions.
- liquid solutions such as an effective amount of the polymer-bound composition dissolved in diluents, such as water or saline
- diluents such as water or saline
- capsules, sachets or tablets each containing a predetermined amount of the active ingredient, as solids or granules
- suspensions in an appropriate liquid and (d) suitable emulsions.
- Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers.
- Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addit n to the active ingredient, such carriers as are known in the art.
- a flavor usually sucrose and acacia or tragacanth
- pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addit n to the active ingredient, such carriers as are known in the art.
- Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
- the formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
- Transurethral administration of the drug is preferred, although not essential.
- the term "transurethral” is used to refer to delivery of the drug into the urethra, such that the drug contacts and passes through the wall of the urethra.
- transurethral administration of a drug can be carried out in a number of different ways.
- the drug can be introduced into the urethra from a flexible tube, squeeze bottle, pump or aerosol spray.
- the drug may also be contained in coatings, pellets or suppositories, which are absorbed, melted or bioeroded in the urethra.
- the drug is included in a coating on the exterior surface of a penile insert.
- a preferred drug delivery device for administering a drug transurethrally is shown in Figure 1.
- a transurethral drug delivery device is shown generally at 10.
- the device comprises a transurethral insert 11 having an easily graspable segment 12 that has opposing symmetrically concave surfaces 13 and 14 adapted to be held by two fingers.
- a drug is contained within the shaft 15, which is sized to fit within the urethra.
- a longitudinal plunger, the top of which is seen at 16, is slidably insertable into the longitudinal bore contained within shaft 15.
- shaft 15 is inserted into the urethra, and plunger tip 16 is pushed into segment 12.
- the inserter 11 is then removed. Prior to use, and during storage, the device is capped with elongate cap
- FIG. 1 is a preferred configuration, other inserter/container configurations can be used and any mechanism by which a predetermined quantity of drug can be introduced from the inserter at a predetermined depth in the urethra is suitable for use with this invention. Examples of other such devices are those described and illustrated in W091/16021, incorporated by reference above.
- the devices can either be manufactured under sterile conditions, thereby eliminating the need for post- manufacturing sterilization, or they can be manufactured under non-sterile conditions and then subsequently sterilized by any suitable technique, e.g., radiation sterilization.
- the devices can be manufactured by typical plastic forming and coating processes known in the art, including molding extrusion, heat forming, dip coating, and the like.
- Transdermal drug administration involves the delivery of a pharmaceutical agent via percutaneous passage of the drug into the systemic circulation of the patient. See Transdermal Drug Delivery: Developmental Issues and Research Initiatives, Hadgraft and Guy (eds.), Marcel Dekker, Inc., (1989); Controlled Drug Delivery:
- transdermal patches may be used in the method described herein.
- a simple adhesive patch can be used which is prepared from a backing material and an acrylate adhesive.
- the adhesive layer is formulated so that a drug, and any carriers or enhancers to be used, are contained therein.
- a hydrogel matrix patch can be used in which a drug, water and, typically, hydrophilic polymers, are used to form a hydrogel, which is then incorporated into a transdermal patch between the backing and the adhesive layer.
- patch configurations can be used as well, including liquid reservoir patches, foam matrix patches, and the like. See, e.g., U.S. Patent Nos.
- compositions and/or transdermal patches may be formulated with one or more preservatives or bacteriostatic agents, e.g., methyl hydroxybenzoate, propyl hydroxybenzoate, chlorocresol, benzalkonium chloride, or the like.
- the dose administered to an animal, particularly a human, in the context of the present invention should be sufficient to effect a penile erection in the male over a reasonable time frame.
- the dose will be determined by the strength of the particular nitric oxide-releasing agent employed, the type of delivery means employed, the route of administration, the condition and weight of the animal to be treated, the timing of administration, i.e., with respect to sexual intercourse, frequency of administration, and the length of time of administration.
- the size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that might accompany the administration of a particular composition or delivery means.
- a suitable dose for example, is about 0.002 mg- 100 mg of nitric oxide.
- the dose can be administered acutely or chronically, preferably acutely.
- nitric oxide was recovered from this polymer on treatment with acid at the rate of 8 nmol of NO per milligram of solid.
- This example illustrates the preparation of a polymer-bound nitric oxide/nucleophile adduct in which the N 2 0 2 " functional group is bound directly to an atom in the polymer backbone.
- a slurry of 10.0 g of polyethyleneimine on silica gel (Aldrich) in 150 ml of acetonitrile was stirred for 3 days under a NO pressure of 5 at or 75-80 psig.
- the resulting orange solid was filtered, washed with acetonitrile and then ether, and dried .in vacuo for 6 h.
- This example illustrates the preparation of a polymer containing nitric oxide-releasing N 2 0 2 " groups that are attached to nucleophile residues pendant on the polymer backbone by the reaction of a primary amine with a derivatized polystyrene.
- An aminostyrene polymer was prepared by warming 3.0 g of chloromethylated polystyrene (1% divinylbenzene; 1.09 mEq Cl per gram; 200-400 mesh; Polysciences, Inc., Warrington, PA) in 20 ml of n-propyl-1,3-propanediamine to 60 ⁇ C in an oil bath and swirling periodically for 5 days. The polymer was then filtered, washed repeatedly with water, then methanol and finally dichloromethane, and dried in vacuo for 24 h. Elemental analysis showed this material to be 2.21% nitrogen, indicating that approximately 80% of the chlorines had been replaced by propylpropanediamino groups.
- nitric oxide can be recovered from the N 2 0 2 " group-containing polymers described above.
- Example 4 This example illustrates the preparation of a polyethylene glycol-based NO-releasing polymer using two different methods of preparation. In both methods, the polymer-bound nitric oxide/nucleophile complex is formed by coprecipitation of a monomeric form of nitric- oxide/nucleophile compound with a polymer.
- Example 5 This example illustrates the preparation of a polymer composed of a polyamine/nitric oxide complex, N- [4-[l-(3-aminopropyl)-2-hydroxy-2- nitrosohydrazino)butyl]-l,3-propanediamine, zwitterionic form (SPER/NO) ; and polyethylene glycol (PEG) formed by the coprecipitation of the polymer and nitric oxide/nucleophilic agent.
- SPER/NO zwitterionic form
- PEG polyethylene glycol
- Example 6 This example describes the use of DEA/NO and SPER/NO to induce an erection in the anesthetized cat.
- the anesthetized cat is a well-established model of erectile response for humans. Unlike other animal models that have been employed, the cat displays both structural and pharmacological similarities to erectile response in men. For example, with the exception of some primate species, the cat is the only animal model in which response to both NO donors and prostaglandins can be observed.
- Figure 2 is a graph of corporal pressure (mm Hg) versus dose ( ⁇ g/200 ⁇ l) and depicts copropral pressure response to intracavemosal injection of NONOates in anesthetized cats. The results are expressed as mean ⁇ SEM of the intracavemosal pressure response in each animal.
- the control is papaverine, 1.65 mg; phentolamine, 25 ⁇ g; and prostaglandin El, 0.5 ⁇ g, in a 200 ⁇ l injection volume.
- Compound A is DEA/NO
- compound B is prostaglandin El (PGEl)
- compound C is SPER/NO
- compound D is SNP.
- Figure 3 is a graph of penile length change versus dose ( ⁇ g/200 ⁇ l) and depicts penile length change in response to intracavemosal injection of NONOates in anesthetized cats. Results are expressed as mean ⁇ SEM of the change in penile length from the length recorded after vehicle administration in each animal.
- the control is papaverine, 1.65 mg; phentolamine, 25 ⁇ g; and prostaglandin El, 0.5 ⁇ g, in a 200 ⁇ l injection volume.
- Compound A is DEA/NO
- compound B is prostaglandin El (PGEl)
- compound C is SPER/NO
- compound D is SNP.
- DEA/NO produced erections of comparable pressure, size and duration to that produced by combined treatment with papaverine, phentolamine and PGEl, which has been successfully used to treat men with organic dysfunction.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL96322742A PL322742A1 (en) | 1995-04-10 | 1996-04-10 | Application of nitrogen oxide releasing agents in treading impotency |
JP8531124A JPH11508872A (en) | 1995-04-10 | 1996-04-10 | Use of nitric oxide releasing drugs to treat impotence |
EP96911665A EP0820294A1 (en) | 1995-04-10 | 1996-04-10 | Use of nitric oxide-releasing agents to treat impotency |
AU54480/96A AU5448096A (en) | 1995-04-10 | 1996-04-10 | Use of nitric oxide-releasing agents to treat impotency |
NO974680A NO974680L (en) | 1995-04-10 | 1997-10-10 | Use of agents which release nitrogen-containing oxide for the treatment of impotence |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/419,044 US5910316A (en) | 1992-08-24 | 1995-04-10 | Use of nitric oxide-releasing agents to treat impotency |
US08/419,044 | 1995-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996032118A1 true WO1996032118A1 (en) | 1996-10-17 |
Family
ID=23660566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/004889 WO1996032118A1 (en) | 1995-04-10 | 1996-04-10 | Use of nitric oxide-releasing agents to treat impotency |
Country Status (11)
Country | Link |
---|---|
US (2) | US5910316A (en) |
EP (1) | EP0820294A1 (en) |
JP (1) | JPH11508872A (en) |
KR (1) | KR19980703796A (en) |
AU (1) | AU5448096A (en) |
CA (1) | CA2217863A1 (en) |
CZ (1) | CZ320497A3 (en) |
HU (1) | HUP9801591A3 (en) |
NO (1) | NO974680L (en) |
PL (1) | PL322742A1 (en) |
WO (1) | WO1996032118A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2774594A1 (en) * | 1998-02-12 | 1999-08-13 | Philippe Gorny | Use of a combination for treating e.g. lack of sexual desire, failure to reach orgasm or decrease or absence of vaginal lubrication |
EP1018879A1 (en) * | 1996-02-02 | 2000-07-19 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
WO2000054773A1 (en) * | 1999-03-12 | 2000-09-21 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
JP2002505676A (en) * | 1997-06-23 | 2002-02-19 | クイーンズ ユニバーシティー アット キングストン | Microdose therapy |
US6747063B2 (en) | 1996-04-23 | 2004-06-08 | Cellegy Pharmaceuticals, Inc. | Combination therapy for treatment of erectile dysfunction |
WO2006128742A2 (en) * | 2005-06-01 | 2006-12-07 | Nolabs Ab | Treatment and pre-treatment device, and manufacturing method therefor, involving nitric oxide |
EP1731176A1 (en) * | 2005-06-01 | 2006-12-13 | NOLabs AB | Pre-treatment device comprising nitric oxide |
US8282967B2 (en) | 2005-05-27 | 2012-10-09 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
US8981139B2 (en) | 2011-02-28 | 2015-03-17 | The University Of North Carolina At Chapel Hill | Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same |
US9526738B2 (en) | 2009-08-21 | 2016-12-27 | Novan, Inc. | Topical gels and methods of using the same |
US9919072B2 (en) | 2009-08-21 | 2018-03-20 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5910316A (en) * | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
US6323211B1 (en) * | 1996-02-02 | 2001-11-27 | Nitromed, Inc. | Compositions and methods for treating sexual dysfunctions |
US20050065161A1 (en) * | 1996-02-02 | 2005-03-24 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
US6294517B1 (en) | 1996-02-02 | 2001-09-25 | Nitromed, Inc. | Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
CA2650204A1 (en) | 1996-12-31 | 1998-07-09 | Harry B. Demopoulos | Pharmaceutical preparations of glutathione and methods of administration thereof |
US6896899B2 (en) * | 1996-12-31 | 2005-05-24 | Antioxidant Pharmaceuticals Corp. | Pharmaceutical preparations of glutathione and methods of administration thereof |
US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
US20040043068A1 (en) * | 1998-09-29 | 2004-03-04 | Eugene Tedeschi | Uses for medical devices having a lubricious, nitric oxide-releasing coating |
US20040151785A1 (en) * | 1998-10-06 | 2004-08-05 | Diamedica Inc. | Method for treating insulin resistance through hepatic nitric oxide |
CA2381095C (en) * | 1998-10-06 | 2012-08-14 | The University Of Manitoba | Method for treating insulin resistance through hepatic nitric oxide |
FR2786699B1 (en) * | 1998-12-02 | 2002-10-04 | Philippe Gorny | MEDICINE, IN PARTICULAR FOR PREVENTING OR TREATING SEXUAL DYSFUNCTIONS |
CA2353531A1 (en) * | 1999-09-02 | 2001-03-08 | Rice University | Nitric oxide-producing hydrogel materials |
US7279176B1 (en) | 1999-09-02 | 2007-10-09 | Rice University | Nitric oxide-producing hydrogel materials |
US7052711B2 (en) * | 1999-09-02 | 2006-05-30 | Rice University | Nitric oxide-producing hydrogel materials |
US6270779B1 (en) * | 2000-05-10 | 2001-08-07 | United States Of America | Nitric oxide-releasing metallic medical devices |
EA005649B1 (en) | 2000-08-11 | 2005-04-28 | Дэвид Р. Уитлок | Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same |
US9080146B2 (en) | 2001-01-11 | 2015-07-14 | Celonova Biosciences, Inc. | Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface |
US6899703B2 (en) * | 2001-03-13 | 2005-05-31 | Clemson University | Intraurethral device for treating or detecting various diseases or infections of the urinary system |
US6558312B2 (en) | 2001-03-13 | 2003-05-06 | Clemson University | Intraurethral device for incontinence |
EP1406608B1 (en) | 2001-05-02 | 2009-07-29 | Nitromed, Inc. | Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use |
US6867194B2 (en) | 2001-08-09 | 2005-03-15 | Wayne State University | Enzyme activated nitric oxide donors |
EP1436018A1 (en) * | 2001-09-26 | 2004-07-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Nitric oxide-releasing coated medical devices and method of preparing same |
US6703046B2 (en) | 2001-10-04 | 2004-03-09 | Medtronic Ave Inc. | Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use |
BR0306868A (en) * | 2002-01-11 | 2005-04-12 | David R Whitlock | Compositions including ammonia oxidizing bacteria and methods for using them |
CA2480033C (en) * | 2002-03-21 | 2011-05-10 | The University Of Utah Research Foundation | In vivo use of glutathionone s-transferase activated nitric oxide donors |
AU2003234510A1 (en) * | 2002-05-07 | 2003-11-11 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt | Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same |
WO2003095623A2 (en) * | 2002-05-10 | 2003-11-20 | The Trustees Of Columbia University In The City Of New York | Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof |
DK1505871T3 (en) * | 2002-05-10 | 2013-05-13 | Univ Miami | Conservation of RNA and Morphology in Cells and Tissues |
JP2007502831A (en) * | 2003-08-20 | 2007-02-15 | ニトロメッド インコーポレーティッド | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
US20070238740A1 (en) * | 2003-08-28 | 2007-10-11 | Nitromed, Inc. | Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use |
CA2539974A1 (en) * | 2003-09-26 | 2005-04-07 | David R. Whitlock | Methods of using ammonia oxidizing bacteria |
US20090131342A1 (en) * | 2004-01-22 | 2009-05-21 | Nitromed, Inc. | Nitrosated and/or nitrosylated compounds, compositions and methods of use |
US7569559B2 (en) * | 2004-02-09 | 2009-08-04 | Noxilizer, Inc. | Nitric oxide-releasing molecules |
US7829553B2 (en) * | 2004-02-09 | 2010-11-09 | Amulet Pharmaceuticals, Inc. | Nitric oxide-releasing polymers |
AU2005289414B2 (en) | 2004-09-27 | 2010-12-09 | Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services | Nitric oxide-releasing diazeniumdiolated acrylonitrile-based polymers, and compositions, medical devices, and uses thereof |
US8067464B2 (en) | 2004-10-04 | 2011-11-29 | Nitromed, Inc. | Compositions and methods using apocynin compounds and nitric oxide donors |
EP1814535A4 (en) * | 2004-11-08 | 2008-06-04 | Nitromed Inc | Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders |
EP1757278A1 (en) * | 2005-08-23 | 2007-02-28 | NOLabs AB | Device, system, and method comprising microencapsulated liquid for release of nitric oxide from a polymer |
US20060188528A1 (en) * | 2005-02-23 | 2006-08-24 | Ansell Healthcare Products Llc | Spreadable warming lubricant |
US7709428B2 (en) * | 2005-02-23 | 2010-05-04 | Ansell Healthcare Products Llc | Thickened spreadable warming lubricant |
EP1858863A1 (en) * | 2005-02-28 | 2007-11-28 | Nitromed, Inc. | Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use |
US20090215838A1 (en) * | 2005-03-09 | 2009-08-27 | Nitromed, Inc. | Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use |
WO2006100154A1 (en) | 2005-03-24 | 2006-09-28 | Nolabs Ab | Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor |
EP1704876A1 (en) * | 2005-03-24 | 2006-09-27 | NOLabs AB | Cosmetic treatment, device for performing said treatment and manufacturing method thereof |
EP1865770A4 (en) * | 2005-04-07 | 2010-12-29 | Nitromed Inc | The genetic risk assessment in heart failure: impact of the genetic variation of nos3 |
EP1883614A4 (en) * | 2005-05-23 | 2010-04-14 | Nicox Sa | Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use |
JP2009511087A (en) * | 2005-06-20 | 2009-03-19 | アビームーア メディカル インコーポレイテッド | Drug delivery products, accessories, and systems |
EP1915157A4 (en) * | 2005-08-02 | 2010-09-01 | Nicox Sa | Nitric oxide enhancing antimicrobial compounds, compositions and methods of use |
WO2007024501A2 (en) * | 2005-08-25 | 2007-03-01 | Medtronic Vascular, Inc. | Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore |
EP1945030A4 (en) * | 2005-10-04 | 2009-10-21 | Nitromed Inc | The genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor gly389arg polymorphism |
US7928079B2 (en) * | 2005-10-31 | 2011-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates |
WO2007059311A2 (en) * | 2005-11-16 | 2007-05-24 | Nitromed, Inc. | Furoxan compounds, compositions and methods of use |
EP1968615A4 (en) * | 2005-12-06 | 2010-08-04 | Amulet Pharmaceuticals Inc | Nitric oxide-releasing polymers |
EP1968584A2 (en) * | 2005-12-20 | 2008-09-17 | Nitromed, Inc. | Nitric oxide enhancing glutamic acid compounds, compositions and methods of use |
CA2647859C (en) | 2006-03-29 | 2016-01-05 | Nitromed, Inc. | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use |
US8241619B2 (en) | 2006-05-15 | 2012-08-14 | Medtronic Vascular, Inc. | Hindered amine nitric oxide donating polymers for coating medical devices |
US8642093B2 (en) * | 2007-10-30 | 2014-02-04 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
US20090112197A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc | Devices configured to facilitate release of nitric oxide |
US8221690B2 (en) * | 2007-10-30 | 2012-07-17 | The Invention Science Fund I, Llc | Systems and devices that utilize photolyzable nitric oxide donors |
US20110190604A1 (en) * | 2006-12-22 | 2011-08-04 | Hyde Roderick A | Nitric oxide sensors and systems |
US7862598B2 (en) * | 2007-10-30 | 2011-01-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
US7811600B2 (en) * | 2007-03-08 | 2010-10-12 | Medtronic Vascular, Inc. | Nitric oxide donating medical devices and methods of making same |
US8273828B2 (en) * | 2007-07-24 | 2012-09-25 | Medtronic Vascular, Inc. | Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation |
US8770201B2 (en) * | 2007-10-26 | 2014-07-08 | Glycobiosciences Inc. | Condom with multifunctional coating |
US10080823B2 (en) | 2007-10-30 | 2018-09-25 | Gearbox Llc | Substrates for nitric oxide releasing devices |
US8980332B2 (en) | 2007-10-30 | 2015-03-17 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
US20090112055A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Sleeves configured to facilitate release of nitric oxide |
US8349262B2 (en) * | 2007-10-30 | 2013-01-08 | The Invention Science Fund I, Llc | Nitric oxide permeable housings |
US8877508B2 (en) * | 2007-10-30 | 2014-11-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
US7897399B2 (en) | 2007-10-30 | 2011-03-01 | The Invention Science Fund I, Llc | Nitric oxide sensors and systems |
US20090222088A1 (en) * | 2008-02-29 | 2009-09-03 | Medtronic Vascular, Inc. | Secondary Amine Containing Nitric Oxide Releasing Polymer Composition |
CN102014870A (en) | 2008-03-07 | 2011-04-13 | 犹他州大学研究基金会 | Activated nitric oxide donors and methods of making and using thereof |
US20090232868A1 (en) * | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Nitric Oxide Releasing Polymer Composition |
US20090232863A1 (en) * | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers |
US8158187B2 (en) * | 2008-12-19 | 2012-04-17 | Medtronic Vascular, Inc. | Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices |
US8425837B2 (en) | 2009-02-23 | 2013-04-23 | Noxilizer, Inc. | Device and method for gas sterilization |
US8709465B2 (en) * | 2009-04-13 | 2014-04-29 | Medtronic Vascular, Inc. | Diazeniumdiolated phosphorylcholine polymers for nitric oxide release |
AR077041A1 (en) | 2009-06-09 | 2011-07-27 | Prolong Pharmaceuticals Inc | HEMOGLOBIN COMPOSITIONS. METHODS |
EP2485734B1 (en) | 2009-10-09 | 2014-07-02 | Merck Sharp & Dohme Corp. | Diuretics |
US20110139163A1 (en) * | 2009-12-15 | 2011-06-16 | Hillila David J | Vibration apparatus for stimulating paranasal sinuses |
KR101024434B1 (en) * | 2009-12-18 | 2011-03-23 | 구인옥 | Support-device to improve impotence |
US9265750B1 (en) | 2010-02-22 | 2016-02-23 | Gene C. Benckini | Apparatus and method for correction of erectile dysfunction |
WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
BR112012033341B1 (en) | 2010-06-30 | 2022-08-23 | Cyclerion Therapeutics, Inc | SGC STIMULATORS |
NZ609955A (en) | 2010-11-09 | 2015-05-29 | Ironwood Pharmaceuticals Inc | Sgc stimulators |
ES2804263T3 (en) | 2011-07-05 | 2021-02-05 | Novan Inc | Topical compositions |
EP2797915B1 (en) | 2011-12-27 | 2016-07-13 | Ironwood Pharmaceuticals, Inc. | 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure |
WO2013173923A1 (en) | 2012-05-25 | 2013-11-28 | Diamedica, Inc. | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
DK2854841T3 (en) | 2012-06-04 | 2017-05-22 | Diamedica Inc | Kallikrein-1-glycosylation isoforms of human tissue |
CN103690490B (en) * | 2012-08-23 | 2017-11-17 | 尼奥克斯(文莱)控股有限公司 | Nitric oxide production system and method are produced based on microencapsulated chemical agent delay |
US9309235B2 (en) | 2012-09-18 | 2016-04-12 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
US9487508B2 (en) | 2012-09-19 | 2016-11-08 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
US8883857B2 (en) | 2012-12-07 | 2014-11-11 | Baylor College Of Medicine | Small molecule xanthine oxidase inhibitors and methods of use |
US9855211B2 (en) | 2013-02-28 | 2018-01-02 | Novan, Inc. | Topical compositions and methods of using the same |
HUE059178T2 (en) | 2013-03-15 | 2022-10-28 | Cyclerion Therapeutics Inc | Sgc stimulators |
ES2836132T3 (en) | 2013-08-08 | 2021-06-24 | Novan Inc | Topical compositions and methods of using them |
WO2015089182A1 (en) | 2013-12-11 | 2015-06-18 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
EP3094327A1 (en) | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
US11225640B2 (en) | 2014-04-15 | 2022-01-18 | Aobiome Llc | Ammonia oxidizing bacteria for treatment of psoriasis |
AU2015247710B2 (en) | 2014-04-15 | 2021-09-09 | Aobiome Llc | Ammonia-oxidizing Nitrosomonas eutropha strain D23 |
CN105813617B (en) | 2014-08-08 | 2021-05-28 | 诺万公司 | Topical compositions and methods of using the same |
EP3194382B1 (en) | 2014-09-17 | 2021-09-08 | Cyclerion Therapeutics, Inc. | Pyrazole derivatives as sgc stimulators |
MX2017003518A (en) | 2014-09-17 | 2017-07-28 | Ironwood Pharmaceuticals Inc | Sgc stimulators. |
WO2016044445A2 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
WO2017151905A1 (en) | 2016-03-02 | 2017-09-08 | Novan, Inc. | Compositions for treating inflammation and methods of treating the same |
CN109310630A (en) | 2016-04-13 | 2019-02-05 | 诺万公司 | For treating composition, system, kit and the method for infection |
KR20230074840A (en) | 2016-07-07 | 2023-05-31 | 사이클리온 테라퓨틱스, 인크. | Solid forms of an sgc stimulator |
CN109476686B (en) | 2016-07-07 | 2022-01-18 | 赛克里翁治疗有限公司 | Phosphorus prodrugs of sGC stimulators |
US11186681B2 (en) | 2016-10-07 | 2021-11-30 | The University Of North Carolina At Chapel Hill | S-Nitrosothiol-mediated hyperbranched polyesters |
EP3565848A4 (en) | 2017-01-03 | 2020-09-02 | The University of North Carolina at Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
AU2018230478A1 (en) | 2017-03-09 | 2019-09-12 | Diamedica Inc. | Dosage forms of tissue kallikrein 1 |
AU2018247167A1 (en) | 2017-03-28 | 2019-09-26 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto |
CA3091458A1 (en) | 2018-03-06 | 2019-09-12 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
KR102088809B1 (en) * | 2018-06-20 | 2020-03-13 | 연세대학교 산학협력단 | A nitric oxide carrier and a method for manufacturing the same |
CA3124673A1 (en) | 2018-12-28 | 2020-07-02 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto |
US20230337678A1 (en) | 2020-02-07 | 2023-10-26 | Know Bio, Llc | Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993015779A1 (en) * | 1992-02-07 | 1993-08-19 | Anthony Ernest Bolton | Method of increasing the concentration of nitric oxide in blood |
CA2106105A1 (en) * | 1993-09-14 | 1995-03-15 | Larry K. Keefer | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
US5405919A (en) * | 1992-08-24 | 1995-04-11 | The United States Of America As Represented By The Secretary Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders |
US5439938A (en) * | 1993-04-07 | 1995-08-08 | The Johns Hopkins University | Treatments for male sexual dysfunction |
WO1995024898A1 (en) * | 1994-03-17 | 1995-09-21 | Comedicus, Incorporated | Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE211789C (en) | ||||
US3153094A (en) * | 1959-06-10 | 1964-10-13 | Du Pont | Nitrosamine manufacture |
NL145762B (en) * | 1970-05-27 | 1975-05-15 | Sandoz Ag | PROCESS FOR PREPARING A PHARMACEUTICAL PREPARATION WITH HYPOTENSIVE / ANTIHYPERTENSIVE ACTION AND FORMED PREPARATION. |
US3826832A (en) * | 1970-06-08 | 1974-07-30 | Sandoz Ag | N-substituted amino-n-nitro-amino-acetonitriles as anti-anginal agents |
US4127118B1 (en) * | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
US4265714A (en) * | 1980-03-24 | 1981-05-05 | General Electric Company | Gas sensing and measuring device and process using catalytic graphite sensing electrode |
US4482533A (en) * | 1982-01-11 | 1984-11-13 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing propranolol |
DD211789A1 (en) * | 1982-08-25 | 1984-07-25 | Adw Ddr | PROCESS FOR PREPARING POLYHYDROXYPOLYMER ESTERS, ESPECIALLY CELLULOSE ESTERS |
US4638079A (en) * | 1985-01-17 | 1987-01-20 | Mallinckrodt, Inc. | Inhibiting polymerization of ethylenically unsaturated monomers |
US4708854A (en) * | 1986-03-10 | 1987-11-24 | The Dow Chemical Company | Process for the removal of NO from fluid streams using a water-soluble polymeric chelate of a polyvalent metal |
US4829991A (en) * | 1987-01-06 | 1989-05-16 | Medical Engineering Corp. | Method and device for stimulating an erection |
US4801587A (en) * | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
JPS63260971A (en) * | 1987-04-20 | 1988-10-27 | Hitachi Chem Co Ltd | Radiation-curable pressure-sensitive adhesive composition |
US4952289A (en) * | 1988-05-09 | 1990-08-28 | Aquanautics Corporation | Macrocyclic amine complexes for ligand extraction and generation |
US5094815A (en) * | 1988-05-18 | 1992-03-10 | Cornell Research Foundation, Inc. | Photolytic interface for HPLC-chemiluminescence detection of non volatile N-nitroso compounds |
US5025001A (en) * | 1988-06-15 | 1991-06-18 | Brigham And Women's Hospital | S-nitroso derivatives of ACE inhibitors and the use thereof |
SE463851B (en) * | 1988-09-02 | 1991-02-04 | Amsu Ltd | COMPOSITION FOR TREATMENT OF ERECT DYSFUNCTION THROUGH URETRA |
US4954526A (en) * | 1989-02-28 | 1990-09-04 | The United States Of America As Represented By The Department Of Health And Human Services | Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents |
US5059603A (en) * | 1989-06-12 | 1991-10-22 | Centuries Laboratories, Inc. | Method and composition for treating impotence |
US4921683A (en) * | 1989-06-20 | 1990-05-01 | The Dow Chemical Company | Nitric oxide abatement with polymeric cobalt(III) chelates |
US5039705A (en) * | 1989-09-15 | 1991-08-13 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
US5212204A (en) * | 1989-10-18 | 1993-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | Antihypertensive compositions and use thereof |
FR2653337B1 (en) * | 1989-10-23 | 1992-02-07 | Dow Corning Sa | SUSTAINED RELEASE ELEMENT AND METHOD FOR MANUFACTURING THE SAME. |
US5242391A (en) * | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
US5087671A (en) * | 1990-06-25 | 1992-02-11 | The Curators Of The University Of Missouri | Polymers for scavenging nitrosating agents |
US5155137A (en) * | 1990-09-20 | 1992-10-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Complexes of nitric oxide with polyamines |
US5087631A (en) * | 1990-12-18 | 1992-02-11 | Glaxo Inc. | Oxathi(SIV)azol-5-one compounds |
US5380758A (en) * | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
JPH06506690A (en) * | 1991-04-19 | 1994-07-28 | ザ チルドレンズメディカルセンター コーポレーション | Methods for blocking neuronal damage mediated by NMDA receptor complexes |
DE69223157T2 (en) * | 1991-09-24 | 1998-06-10 | Us Health | OXYGEN-SUBSTITUTED DERIVATIVES OF NUCLEOPHIL NITROGEN OXIDE ADDUCTS AND THEIR USE AS NITROGEN OXIDE DONOR PRODRUGS |
US5389675A (en) * | 1992-03-27 | 1995-02-14 | The United States Of America As Represented By The Department Of Health And Human Services | Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents |
WO1993020806A1 (en) * | 1992-04-13 | 1993-10-28 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of nitric oxide/nucleophile complexes for the treatment of cancer |
US5910316A (en) * | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
US5427797A (en) * | 1993-04-06 | 1995-06-27 | Brigham And Women's Hospital | Systemic effects of nitric oxide inhalation |
ATE194769T1 (en) * | 1993-10-08 | 2000-08-15 | Us Health | USE OF NITROGEN OXIDE RELEASING COMPOUNDS AS MEDICINAL AGENTS FOR RADIATION SENSITIZATION FOR HYPOXIC CELLS |
US5482039A (en) * | 1994-03-25 | 1996-01-09 | Vivus, Inc. | Process for diagnosing erectile dysfunction, and related methods of treatment |
-
1995
- 1995-04-10 US US08/419,044 patent/US5910316A/en not_active Expired - Fee Related
-
1996
- 1996-04-10 EP EP96911665A patent/EP0820294A1/en not_active Withdrawn
- 1996-04-10 JP JP8531124A patent/JPH11508872A/en active Pending
- 1996-04-10 KR KR1019970707196A patent/KR19980703796A/en not_active Application Discontinuation
- 1996-04-10 PL PL96322742A patent/PL322742A1/en unknown
- 1996-04-10 CA CA002217863A patent/CA2217863A1/en not_active Abandoned
- 1996-04-10 CZ CZ973204A patent/CZ320497A3/en unknown
- 1996-04-10 AU AU54480/96A patent/AU5448096A/en not_active Abandoned
- 1996-04-10 HU HU9801591A patent/HUP9801591A3/en unknown
- 1996-04-10 WO PCT/US1996/004889 patent/WO1996032118A1/en not_active Application Discontinuation
-
1997
- 1997-10-10 NO NO974680A patent/NO974680L/en not_active Application Discontinuation
-
1999
- 1999-04-09 US US09/289,570 patent/US6290981B1/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993015779A1 (en) * | 1992-02-07 | 1993-08-19 | Anthony Ernest Bolton | Method of increasing the concentration of nitric oxide in blood |
US5405919A (en) * | 1992-08-24 | 1995-04-11 | The United States Of America As Represented By The Secretary Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders |
US5439938A (en) * | 1993-04-07 | 1995-08-08 | The Johns Hopkins University | Treatments for male sexual dysfunction |
CA2106105A1 (en) * | 1993-09-14 | 1995-03-15 | Larry K. Keefer | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
WO1995024898A1 (en) * | 1994-03-17 | 1995-09-21 | Comedicus, Incorporated | Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1018879A1 (en) * | 1996-02-02 | 2000-07-19 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
EP1018879A4 (en) * | 1996-02-02 | 2002-07-24 | Nitromed Inc | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
US6747063B2 (en) | 1996-04-23 | 2004-06-08 | Cellegy Pharmaceuticals, Inc. | Combination therapy for treatment of erectile dysfunction |
JP2002505676A (en) * | 1997-06-23 | 2002-02-19 | クイーンズ ユニバーシティー アット キングストン | Microdose therapy |
FR2774594A1 (en) * | 1998-02-12 | 1999-08-13 | Philippe Gorny | Use of a combination for treating e.g. lack of sexual desire, failure to reach orgasm or decrease or absence of vaginal lubrication |
WO2000054773A1 (en) * | 1999-03-12 | 2000-09-21 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
US9403852B2 (en) | 2005-05-27 | 2016-08-02 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US8962029B2 (en) | 2005-05-27 | 2015-02-24 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US11691995B2 (en) | 2005-05-27 | 2023-07-04 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US8282967B2 (en) | 2005-05-27 | 2012-10-09 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US9403851B2 (en) | 2005-05-27 | 2016-08-02 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US8956658B2 (en) | 2005-05-27 | 2015-02-17 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
WO2006128742A2 (en) * | 2005-06-01 | 2006-12-07 | Nolabs Ab | Treatment and pre-treatment device, and manufacturing method therefor, involving nitric oxide |
EP1731176A1 (en) * | 2005-06-01 | 2006-12-13 | NOLabs AB | Pre-treatment device comprising nitric oxide |
WO2006128742A3 (en) * | 2005-06-01 | 2007-04-05 | Nolabs Ab | Treatment and pre-treatment device, and manufacturing method therefor, involving nitric oxide |
US9526738B2 (en) | 2009-08-21 | 2016-12-27 | Novan, Inc. | Topical gels and methods of using the same |
US9737561B2 (en) | 2009-08-21 | 2017-08-22 | Novan, Inc. | Topical gels and methods of using the same |
US9919072B2 (en) | 2009-08-21 | 2018-03-20 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
US10376538B2 (en) | 2009-08-21 | 2019-08-13 | Novan, Inc. | Topical gels and methods of using the same |
US11583608B2 (en) | 2009-08-21 | 2023-02-21 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
US8981139B2 (en) | 2011-02-28 | 2015-03-17 | The University Of North Carolina At Chapel Hill | Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same |
US9713652B2 (en) | 2011-02-28 | 2017-07-25 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing S-nitrosothiol-modified silica particles and methods of making the same |
Also Published As
Publication number | Publication date |
---|---|
US5910316A (en) | 1999-06-08 |
AU5448096A (en) | 1996-10-30 |
JPH11508872A (en) | 1999-08-03 |
HUP9801591A2 (en) | 1999-02-01 |
EP0820294A1 (en) | 1998-01-28 |
PL322742A1 (en) | 1998-02-16 |
US6290981B1 (en) | 2001-09-18 |
CA2217863A1 (en) | 1996-10-17 |
HUP9801591A3 (en) | 2000-06-28 |
NO974680D0 (en) | 1997-10-10 |
CZ320497A3 (en) | 1998-05-13 |
NO974680L (en) | 1997-12-03 |
KR19980703796A (en) | 1998-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6290981B1 (en) | Use of nitric oxide-releasing agents to treat impotency | |
US5676963A (en) | Implants, prostheses, and stents comprising polymer-bound nitric oxide/nucleophile adducts capable of releasing nitric oxide | |
EP0793500B1 (en) | Pharmaceutical compositions comprising nitric oxide-releasing polysaccharides | |
US5525357A (en) | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same | |
US6379660B1 (en) | Nitric oxide-releasing 1-[(2-carboxylato)pyrrolidin-1-yl] diazen-1-ium-1,2-diolates and composition comprising same | |
AU698525B2 (en) | Use of nitric oxide-releasing polymers to treat restenosis and related disorders | |
CA2205555C (en) | Use of nitric oxide-releasing agents for reducing metastasis risk | |
CA2216696C (en) | Polysaccharide-bound nitric oxide-nucleophile adducts | |
US6703046B2 (en) | Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use | |
CA2106105C (en) | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same | |
CA2205564C (en) | Pharmaceutical compositions comprising nitric oxide-releasing biopolymers | |
CN1187771A (en) | Use of nitric oxide-releasing agents to treat imptotency | |
AU695579C (en) | Polysaccharide-bound nitric oxide-nucleophile adducts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96194362.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2217863 Country of ref document: CA Ref document number: 2217863 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1997-3204 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 1996 9024 Country of ref document: AT Date of ref document: 19961017 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 19969024 Country of ref document: AT Ref document number: 1019970707196 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 1996 531124 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996911665 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996911665 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-3204 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970707196 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996911665 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1997-3204 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019970707196 Country of ref document: KR |